Access to DRDO drug 2-DG will improve in weeks: Dr. Reddy’s
The Hindu
DRDO invites more pharma firms to take up its production
Availability of 2-Deoxy-D-Glucose (2-DG), the drug developed by DRDO lab INMAS and approved for use as adjunct in treatment of moderate to severe COVID-19 patients, is set to improve in the weeks ahead with drugmaker Dr. Reddy’s Laboratories ramping up production. “I expect a very significant ramp up in the second half of June and subsequently in July,” said Deepak Sapra, CEO (API and Services) of Dr. Reddy’s. Stating that the company is licensee of DRDO, for the product launched last month following emergency use authorisation from the Drugs Controller General of India, he said in a matter of weeks the capacity will be enhanced to meet requirements of lakhs of patients.More Related News
Around 440 MBBS graduates of 2021 are not required to undergo one year of compulsory rural service as per the bond signed by them while joining the medical course through government-quota seats in 2015 as the High Court of Karnataka has said the law, enacted in 2012 for mandatory rural service, remained unenforced for 10 years as it was published in the official gazette only in July 2022.